Literature DB >> 27888056

Sclerostin expression and functions beyond the osteocyte.

Megan M Weivoda1, Stephanie J Youssef2, Merry Jo Oursler2.   

Abstract

Sclerostin, the product of the SOST gene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes to regulate bone formation. While it is often considered an osteocyte-specific protein, SOST expression has been reported in numerous other cell types, including hypertrophic chondrocytes and cementocytes. Of interest, SOST/sclerostin expression is altered in certain pathogenic conditions, including osteoarthritis and rheumatic joint disease, and it is unclear whether sclerostin plays a protective role or whether sclerostin may mediate disease pathogenesis. Therefore, as anti-sclerostin antibodies are being developed for the treatment of osteoporosis, it is important to understand the functions of sclerostin beyond the regulation of bone formation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis; Sclerostin; Wnt

Mesh:

Substances:

Year:  2016        PMID: 27888056      PMCID: PMC5328839          DOI: 10.1016/j.bone.2016.11.024

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  67 in total

1.  Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.

Authors:  B Y Chan; E S Fuller; A K Russell; S M Smith; M M Smith; M T Jackson; M A Cake; R A Read; J F Bateman; P N Sambrook; C B Little
Journal:  Osteoarthritis Cartilage       Date:  2011-05-12       Impact factor: 6.576

2.  Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.

Authors:  Grigorios T Sakellariou; Athanasios D Anastasilakis; Ilias Bisbinas; Dimitrios Oikonomou; Spyridon Gerou; Stergios A Polyzos; Fares E Sayegh
Journal:  Rheumatology (Oxford)       Date:  2014-10-27       Impact factor: 7.580

3.  SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development.

Authors:  Rutger L van Bezooijen; Marco C Deruiter; Nathalie Vilain; Rui M Monteiro; Annemieke Visser; Lianne van der Wee-Pals; Conny J van Munsteren; Pancras C W Hogendoorn; Michel Aguet; Christine L Mummery; Socrates E Papapoulos; Peter Ten Dijke; Clemens W G M Löwik
Journal:  Dev Dyn       Date:  2007-02       Impact factor: 3.780

4.  Serum sclerostin in alcoholics: a pilot study.

Authors:  E González-Reimers; C Martín-González; M J de la Vega-Prieto; R Pelazas-González; C Fernández-Rodríguez; J López-Prieto; J Alvisa-Negrín; F Santolaria-Fernández
Journal:  Alcohol Alcohol       Date:  2013-01-07       Impact factor: 2.826

5.  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.

Authors:  Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Barrero; Franklin J Asuncion; Denise Dwyer; Chun-Ya Han; Fay Vlasseros; Rana Samadfam; Jacquelin Jolette; Susan Y Smith; Marina Stolina; David L Lacey; William S Simonet; Chris Paszty; Gang Li; Hua Z Ke
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

6.  Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.

Authors:  A Jäger; W Götz; S Lossdörfer; B Rath-Deschner
Journal:  J Periodontal Res       Date:  2009-09-23       Impact factor: 4.419

7.  Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).

Authors:  Brad Sevetson; Scott Taylor; Yang Pan
Journal:  J Biol Chem       Date:  2004-01-22       Impact factor: 5.157

8.  Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study.

Authors:  J Velasco; M T Zarrabeitia; J R Prieto; J L Perez-Castrillon; M D Perez-Aguilar; M I Perez-Nuñez; C Sañudo; J Hernandez-Elena; I Calvo; F Ortiz; J Gonzalez-Macias; J A Riancho
Journal:  Osteoporos Int       Date:  2009-04-17       Impact factor: 4.507

9.  Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.

Authors:  Maria P Yavropoulou; Antoon H van Lierop; Neveen A T Hamdy; Rene Rizzoli; Socrates E Papapoulos
Journal:  Bone       Date:  2012-05-02       Impact factor: 4.398

10.  A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.

Authors:  Monica Florio; Kannan Gunasekaran; Marina Stolina; Xiaodong Li; Ling Liu; Barbara Tipton; Hossein Salimi-Moosavi; Franklin J Asuncion; Chaoyang Li; Banghua Sun; Hong Lin Tan; Li Zhang; Chun-Ya Han; Ryan Case; Amy N Duguay; Mario Grisanti; Jennitte Stevens; James K Pretorius; Efrain Pacheco; Heidi Jones; Qing Chen; Brian D Soriano; Jie Wen; Brenda Heron; Frederick W Jacobsen; Emil Brisan; William G Richards; Hua Zhu Ke; Michael S Ominsky
Journal:  Nat Commun       Date:  2016-05-27       Impact factor: 14.919

View more
  47 in total

Review 1.  Energy Metabolism of Bone.

Authors:  Katherine J Motyl; Anyonya R Guntur; Adriana Lelis Carvalho; Clifford J Rosen
Journal:  Toxicol Pathol       Date:  2017-11-02       Impact factor: 1.902

2.  Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast-Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis.

Authors:  Rosalie M Sterner; Kimberly N Kremer; Amel Dudakovic; Jennifer J Westendorf; Andre J van Wijnen; Karen E Hedin
Journal:  J Immunol       Date:  2018-06-18       Impact factor: 5.422

Review 3.  Skeletal changes during and after spaceflight.

Authors:  Laurence Vico; Alan Hargens
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

4.  Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.

Authors:  Alessandra Piccoli; Francesca Cannata; Rocky Strollo; Claudio Pedone; Giulia Leanza; Fabrizio Russo; Valentina Greto; Camilla Isgrò; Carlo Cosimo Quattrocchi; Carlo Massaroni; Sergio Silvestri; Gianluca Vadalà; Tiziana Bisogno; Vincenzo Denaro; Paolo Pozzilli; Simon Y Tang; Matt J Silva; Caterina Conte; Rocco Papalia; Mauro Maccarrone; Nicola Napoli
Journal:  J Bone Miner Res       Date:  2020-10-02       Impact factor: 6.741

5.  Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.

Authors:  Katya Sapunarova; Vesselina Goranova-Marinova; Pencho Georgiev; Tanya Deneva; Silvia Tsvetkova; Zhanet Grudeva-Popova
Journal:  Ann Med       Date:  2020-03-26       Impact factor: 4.709

6.  [Observation of dendrite osteocytes of mice at different developmental stages using Ploton silver staining and phalloidin staining].

Authors:  Shuhao Feng; Liangxiao Bao; Gengtao Qiu; Zheting Liao; Zhonghao Deng; Nachun Chen; Yuhao Chu; Ziheng Luo; Yu Jin; Xiaoyu Li; Yingzi Yang; Liang Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

Review 7.  Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk.

Authors:  Cy Fixen; Jennifer Tunoa
Journal:  Curr Osteoporos Rep       Date:  2021-01-07       Impact factor: 5.096

8.  Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.

Authors:  Jia Peng; Zhang Dong; Zhang Hui; Wang Aifei; Deng Lianfu; Xu Youjia
Journal:  BMC Musculoskelet Disord       Date:  2021-05-25       Impact factor: 2.362

9.  Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion.

Authors:  J Chen; X Yuan; I Pilawski; X Liu; J Delgado-Calle; T Bellido; H Turkkahraman; J A Helms
Journal:  J Dent Res       Date:  2020-10-20       Impact factor: 6.116

Review 10.  The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.

Authors:  Eugenia Bertoldo; Giovanni Adami; Maurizio Rossini; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti; Angelo Fassio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.